Skip to main content
Retour
Watch Compare

Galera Therapeutics, Inc.

Qualité des données : 83%
GRTX
OTC Manufacturing Chemicals
0,04 €
▲ 0,00 € (2,44%)
Cap. Boursière: 3,09 M
Prix
0,04 €
Cap. Boursière
3,09 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -6,05 M
P/E of 0,02 — trading at a low valuation

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-50,31%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio8,20
Interest CoverageN/A

Valorisation

PE (TTM)
0,02
Au-dessus de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E 0,0 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q32023 -0,40 € -0,33 € +16,9%
Q22023 -0,38 € -0,48 € -26,9%
Q12023 -0,43 € -0,50 € -16,4%
Q42022 -0,51 € -0,58 € -14,8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) 149,05 M
ROE N/A ROA 2697,72%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,05 M
ROIC -50,31% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,20
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,30 M Tangible Book Value -149,22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0,02 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -195,51%
Market Cap 3,09 M Enterprise Value -1,38 M
Per Share
EPS (Diluted TTM) 0,64 Revenue / Share N/A
FCF / Share -0,08 OCF / Share -0,08
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -4,06%
SBC-Adj. FCF -6,92 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income 149,05 M -18,96 M -59,08 M -62,22 M -80,53 M
EPS (Diluted) 0,64 -0,34 — — —
Gross Profit — — — — —
Operating Income -2,54 M -20,16 M -49,26 M -51,23 M -73,37 M
EBITDA — — — — —
R&D Expenses 349 000,0 3,15 M 24,12 M 31,01 M 52,42 M
SG&A Expenses — — — — —
D&A 0,0 20 000,0 259 000,0 114 000,0 778 000,0
Interest Expense 0,0 0,0 11,41 M 11,57 M 7,19 M
Income Tax 0,0 -203 000,0 0,0 70 000,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,20 M 10,10 M 26,14 M 44,04 M 83,31 M
Total Liabilities 645 000,0 153,77 M 157,33 M 153,22 M 141,32 M
Shareholders' Equity 3,97 M -148,04 M -131,19 M -109,18 M -58,00 M
Total Debt — — — — —
Cash & Equivalents 6,38 M 8,29 M 18,26 M 4,27 M 19,86 M
Current Assets 7,10 M 10,00 M 21,63 M 38,54 M 77,39 M
Current Liabilities 645 000,0 1,67 M 4,96 M 13,38 M 12,94 M